📅 PUBMED DAILY TRIAGE — 2026-04-18
Window: 2026-04-17T09:00:00Z → 2026-04-18T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~75 | Candidates evaluated: 65 High priority: 2 | Standard: 8 | Low/archive: 0 | Unsolicited finds: 1 Run status: PARTIAL_SUCCESS
🔴🟠 HIGH PRIORITY (Flag-elevated, 7/10) — Best Finds by Topic
Early Cancer Detection (Liquid Biopsy)
TR-2026-04-18-001 / PMID 41998312 · Identification and validation of liquid biopsy-based methylation biomarkers for germ cell tumor subtypes · 7/10 🔴 EARLY_CANCER_DETECTION
Validated cfDNA-detectable methylation biomarkers (DPP7, APC for YST; GATA4, FBRS for EC) across 719 germ cell tumors — addresses longstanding gap in non-invasive GCT subtyping, particularly for pediatric patients where current protein markers fail. Commun Med (Lond) · 2026-04-17 · Janssen FW et al. (Princess Máxima Center)
Precision Oncology / Genomic Medicine (Deferred from 2026-04-17)
TR-2026-04-18-002 / PMID 41987223 · Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer · 7/10 🟠 NOVEL_TREATMENT
Largest ecDNA/cSV characterization in mCRPC (n=193 + 53 rapid autopsy samples, Hi-C confirmed); identifies convergent ecDNA evolution as an early metastatic event detectable in ctDNA — directly enables resistance monitoring and rational combination trial design. Genome Biology · 2026-04-15 · Moreno-Rodriguez T, Quigley DA et al. (UCSF/Peter MacCallum)
🟢⚪ STANDARD (5–7) — Top by Topic
Hematologic Malignancies
TR-2026-04-18-003 / PMID 41998300 · Intracellular IL-23R regulates mitotic spindle formation in AML · 7/10 · Drug Development
Novel non-canonical IL-23R function in AML with demonstrated selectivity for malignant vs. normal hematopoietic cells (BioID proteomics + primary samples). Leukemia 2026-04-17
TR-2026-04-18-004 / PMID 41997407 · Quizartinib resistance drives clonal FLT3-D835H + TP53-R248W emergence in FLT3-ITD AML · 6/10 · Drug Development
Comprehensive resistance characterization with rational combos (eprenetapopt or trametinib + quizartinib). Eur J Pharmacol 2026-04-15
TR-2026-04-18-005 / PMID 41998301 · PRMT5 inhibition sensitizes DLBCL/MCL to ferroptosis via AKT-MYC-ATF5-SLC7A11 axis · 6/10 · Drug Development
PDX-validated combination (GSK3326595 + DMF) in relapsed/refractory B-cell lymphoma. Leukemia 2026-04-17
Precision Oncology / Genomic Medicine
- TR-2026-04-18-006 / PMID 41998762 · Chromosome 17 imbalance biomarker in HER2-low breast cancer · 6/10 · Genomics/Precision Medicine
Clonal chr17 copy number signature identifies unfavorable HER2-low subgroup — direct implications for T-DXd patient selection. Biomark Res 2026-04-17
Aging/Longevity + Cardiometabolic
- TR-2026-04-18-007 / PMID 41998431 · Rare DNA repair variants × cardiometabolic risk explain cognitive variability; n=376,533 UK Biobank · 6/10 · Genomics/Public Health
60.8% of cognitive associations only detectable via gene × cardiometabolic interaction — supports combined genomic-metabolic dementia risk screening. GeroScience 2026-04-18
GLP-1 / Cardiometabolic
- TR-2026-04-18-008 / PMID 41998799 · GLP-1 therapies and hair loss: systematic review (24 studies) · 5/10 · Public Health
Dose-dependent telogen effluvium with semaglutide ≥2mg/week; females disproportionately affected. Counseling gap identified. Sci Prog 2026-04-17
Novel Therapeutics (CAR-T / Immunotherapy)
- TR-2026-04-18-009 / PMID 41998669 · PPTC7/BNIP3/NIX→cGAS/STING axis augments CAR-T efficacy in multiple myeloma · 5/10 · Treatment Innovation
Mitophagy suppression triggers immunogenic senescence to enhance BCMA-CAR-T killing. J Exp Clin Cancer Res 2026-04-18
💡 UNSOLICITED FINDS
- TR-2026-04-18-010 / PMID 41997807 · Epigenetic biomarkers in neurodegenerative diseases: from molecular signatures to therapeutic targets · 5/10 · Diagnostics
High-impact Trends Neurosci review draws direct parallels from cancer liquid biopsy to neurodegenerative cfDNA epigenetic biomarker development. Trends Neurosci 2026-04-16
📊 TODAY'S BREAKDOWN
By research category:
- Drug Development: 4
- Genomics/Precision Medicine: 3
- Public Health: 1
- Treatment Innovation: 1
- Diagnostics: 1 (unsolicited)
By evidence maturity:
- Exploratory: 6
- Validated: 4
By watchlist topic (reviewed / kept / highest score):
| Topic | Reviewed | Kept | Top Score |
|---|---|---|---|
| Hematologic malignancies | 10 | 3 | 7/10 |
| Early cancer detection / liquid biopsy | 10 | 2 | 7/10 |
| CBC + ML hematology | 0 | 0 | N/A |
| Novel therapeutics / immunotherapy | 10 | 2 | 5/10 |
| GLP-1 / SGLT2 / cardiometabolic | 5 | 2 | 6/10 |
| Precision oncology / genomics | 5 | 2 | 7/10 (deferred) |
| Aging / longevity | 5 | 1 | 6/10 |
| Rare diseases | 0 | 0 | N/A |
| AI/ML clinical diagnostics | 0 | 0 | N/A |
| Deferred PMIDs (2026-04-17) | 3 | 2 | 7/10 |
| Sentinel scan | 5 | 1 | 5/10 (unsolicited) |
By source type: peer_reviewed: 10 | preprint: 0
Topics with zero 8+ articles this run: All topics (highest was 7/10; threshold 8 not reached today)
🔧 RUN NOTES
- Partial coverage: CBC/ML hematology (12th consecutive run with no abstracts retrieved — 23 candidate PMIDs queued for priority fetch next run), Rare diseases (24 IDs not fetched), AI/ML clinical diagnostics (80 IDs not fetched). These represent significant gaps.
- Deferred PMIDs: 1 of 18 deferred PMIDs from 2026-04-17 fully processed (PMID 41987223 → HIGH). 15 PMIDs re-queued to next run's state.json.
- Retraction: PMID 41997759 (AML HMGB1 paper, Biomed Pharmacother 2019) retraction notice identified and excluded from output.
- Sentinel scan truncation: 1157 results found; only top 5 reviewed. 1 unsolicited find (Trends Neurosci neurodegeneration epigenetics review).
- Alert threshold: 2 HIGH articles qualify for Telegram alerts (TR-2026-04-18-001, TR-2026-04-18-002). Max 5 per run — both will be sent.
- Rolling 7-day view — sparse topics: CBC/ML (12 consecutive), Rare diseases (2+ consecutive), AI/ML diagnostics (2 consecutive) — all consistently under-retrieved due to abstract fetch constraints.
- Deferred CBC PMIDs for next run: 41998219, 41998172, 41998063, 41997404, 41996690, 41996637, 41996313, 41996287, 41995871, 41995844 (10 PMIDs)
- Deferred Rare Disease PMIDs: 41998504, 41998457, 41998351, 41997899, 41997800, 41997622, 41997618, 41997562, 41997376, 41996965
- Deferred AI/ML Diagnostics PMIDs: 41998677, 41998625, 41998456, 41998396, 41998114, 41998108, 41997837, 41997788, 41997760, 41998457